Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Reaches New 12-Month Low – Should You Sell?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s share price hit a new 52-week low during trading on Monday . The stock traded as low as $26.41 and last traded at $26.67, with a volume of 40673 shares. The stock had previously closed at $27.21.

Wall Street Analysts Forecast Growth

LKFT has been the subject of several analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, May 26th. Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Morgan Stanley began coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Friday, July 10th. They set an “equal weight” rating and a $30.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Lakefront Biotherapeutics American Depositary Shares presently has a consensus rating of “Hold” and a consensus target price of $34.33.

Lakefront Biotherapeutics American Depositary Shares Stock Down 1.1%

The business’s 50-day moving average price is $28.77 and its 200 day moving average price is $30.31. The company has a market capitalization of $1.74 billion, a P/E ratio of -18.76 and a beta of 0.27.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.52. The firm had revenue of $8.75 million for the quarter, compared to the consensus estimate of $11.26 million. Analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -10.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Hedge funds have recently modified their holdings of the company. ABC Arbitrage SA purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the first quarter valued at approximately $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in Lakefront Biotherapeutics American Depositary Shares in the first quarter worth $248,000. QRG Capital Management Inc. grew its holdings in Lakefront Biotherapeutics American Depositary Shares by 21.9% in the first quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after purchasing an additional 3,535 shares during the period. XTX Topco Ltd boosted its holdings in Lakefront Biotherapeutics American Depositary Shares by 92.6% in the fourth quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock worth $759,000 after acquiring an additional 11,162 shares in the last quarter. Finally, Millennium Management LLC grew its position in Lakefront Biotherapeutics American Depositary Shares by 121.9% during the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after purchasing an additional 186,452 shares during the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.